Trillium Therapeutics (NASDAQ: TRIL) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and target prices for Trillium Therapeutics and SIGA Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 3 0 3.00
SIGA Technologies 0 0 0 0 N/A

Trillium Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 77.22%. Given Trillium Therapeutics’ higher possible upside, research analysts plainly believe Trillium Therapeutics is more favorable than SIGA Technologies.

Earnings & Valuation

This table compares Trillium Therapeutics and SIGA Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$23.96 million ($2.57) -3.07
SIGA Technologies $14.99 million 25.06 -$39.69 million ($0.49) -9.71

Trillium Therapeutics has higher earnings, but lower revenue than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

45.5% of Trillium Therapeutics shares are held by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are held by institutional investors. 4.7% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Trillium Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -248.39% -65.21%
SIGA Technologies -201.85% N/A -23.22%

Volatility & Risk

Trillium Therapeutics has a beta of 13.72, indicating that its stock price is 1,272% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

Trillium Therapeutics beats SIGA Technologies on 7 of the 12 factors compared between the two stocks.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

About SIGA Technologies

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.